Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. [electronic resource]
Producer: 20141210Description: 161-7 p. digitalISSN:- 1872-8332
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease Progression
- Disease-Free Survival
- Drug Administration Schedule
- Drug Resistance, Neoplasm -- genetics
- Drug Synergism
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride
- Female
- Humans
- Hydroxamic Acids -- administration & dosage
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation, Missense
- Quinazolines -- administration & dosage
- Treatment Outcome
- Vorinostat
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.